Table 1. Distribution of markers in serum of Lung Cancer patients and Controls, and efficacy in classifying Lung Cancer.

Marker	Control/Case		Median	Range	p a	AUC (95% CI) b
HB-EGF (pg/mL)	Control		196.50	32.00–4661.00	0.154	0.585 (0.435–0.755)
		Healthy	174.50	65.00–1627.00
		Benign	218.50	32.00–4661.00
	LC		182.50	24.00–1823.00
EGF (pg/mL)	Control		340.82	98.01–1160.42	<0.001	0.701 (0.525–0.853)
		Healthy	247.61	98.01–659.01
		Benign	404.76	102.04–1160.42
	LC		577.18	55.97–1176.89
sEGFR (ng/mL)	Control		34.13	20.82–49.57	0.037	0.619 (0.471–0.786)
		Healthy	30.42	20.82–47.70
		Benign	37.82	25.13–49.57
	LC		37.54	21.90–97.40
sCD26 (ng/mL)	Control		473.00	122.00–998.00	<0.001	0.711 (0.453–0.865)
		Healthy	504.50	331.00–816.00
		Benign	405.50	122.00–998.00
	LC		358.50	136.00–1192.00
VEGF (pg/mL)	Control		542.70	39.73–2631.56	0.055	0.600 (0.449–0.769)
		Healthy	542.70	39.73–1178.40
		Benign	541.29	124.94–2631.56
	LC		619.99	81.54–1856.40
CAL (ng/mL)	Control		129.44	33.13–421.23	<0.001	0.781 (0.627–0.916)
		Healthy	116.55	39.16–274.70
		Benign	141.93	33.13–421.23
	LC		221.21	48.33–482.89

^a Mann-Whitney U (two-sided test).

^b AUC based on out-of-bag predictions (models are fitted in the training sets with the 75% of the cases and are subsequently used for predicting the group membership of the 25% test cases). Average values and percentile 95% CI over 1000 repetitions are provided.